Aragen Life Sciences IPO: ₹800 Cr Fresh Issue & DRHP | DA
Aragen Life Sciences Limited (formerly known as GVK BIO), a premier global contract research, development, and manufacturing organization (CRDMO) headquartered in Hyderabad, has officially registered its Draft Red Herring Prospectus (DRHP) dated 26 August 2026 with the Securities and Exchange Board of India (SEBI). Proposing a Mainboard listing on BSE Limited and the National Stock Exchange of India (NSE), the public offering comprises a Fresh Issue of up to ₹800.00 Crore (₹8,000 Million) and an Offer for Sale (OFS) of up to 2,73,29,192 equity shares (Face Value: ₹10.00) by selling promoter entities and marquee global investor Goldman Sachs Capital Holdings III Pte. Ltd. (which acquired an influential ~33% stake in 2021). In FY2026, Aragen generated ₹2,178.39 Crore in consolidated revenue from operations with an exceptional adjusted operating EBITDA of ₹593.77 Crore (27.26% EBITDA margin) and net profit of ₹257.64 Crore. Primary net proceeds will be deployed to extinguish corporate debt, procure robotic discovery synthesisers at Hyderabad R&D campuses, and expand biologics manufacturing suites in Bengaluru.
1. Aragen Life Sciences IPO at a Glance: Public Issue Architecture
Aragen Life Sciences Limited (formerly known as GVK BIO), a premier global contract research, development, and manufacturing organization (CRDMO), formally registered its Draft Red Herring Prospectus (DRHP) dated 26 August 2026 with the Securities and Exchange Board of India (SEBI).
In the Indian life sciences ecosystem, Aragen stands out as an integrated, pure-play CRDMO bridging discovery chemistry, biology, clinical development, and commercial manufacturing for global innovators. The proposed offering initiates a landmark public market transition for the Hyderabad-headquartered scientific enterprise, with an estimated total issue size ranging between ₹2,500.00 Crore and ₹3,000.00 Crore.
Structured as a balanced capital package, the IPO features a primary Fresh Issue of up to ₹800.00 Crore alongside an Offer for Sale (OFS) of up to 2,73,29,192 equity shares (Face Value: ₹10.00) by selling promoter entities and marquee institutional sponsor Goldman Sachs Capital Holdings III Pte. Ltd. (which acquired a ~33% stake in 2021).
| Offering & Regulatory Parameter | Statutory Metric Disclosed in DRHP | Institutional Verification Status |
|---|---|---|
| Issuer Corporate Identity | Aragen Life Sciences Limited (CIN: U24239TG2000PLC035677) | CONFIRMED |
| DRHP Registration Date with SEBI | Wednesday, 26 August 2026 (SEBI Entry: 103845) | CONFIRMED |
| Fresh Issue Component | Up to ₹800.00 Crore (₹8,000 Million) | CONFIRMED |
| Offer for Sale (OFS) Tranche | Up to 2,73,29,192 Equity Shares | CONFIRMED |
| Statutory Face Value | ₹10.00 per equity share | CONFIRMED |
| Selling Shareholders | Goldman Sachs Capital Holdings III Pte. Ltd. & Promoters | CONFIRMED |
| FY2026 Operational Revenue | ₹2,178.39 Crore (14.64% 2-Year CAGR) | CONFIRMED |
| FY2026 Adjusted Operating EBITDA | ₹593.77 Crore (27.26% EBITDA Margin) | CONFIRMED |
| Price Band & Market Lot Size | To be announced at final RHP registration | NOT YET ANNOUNCED |
| Bidding Calendar (Open/Close) | Subject to SEBI observation clearance | NOT YET ANNOUNCED |
| Proposed Listing Exchanges | BSE Limited & National Stock Exchange (NSE) (Mainboard) | CONFIRMED |
| Registrar to the Offer | KFin Technologies Limited | CONFIRMED |
| Book Running Lead Managers | Goldman Sachs (India), Axis Capital, Citigroup, JM Financial | CONFIRMED |
2. Capital Structure: ₹800 Crore Fresh Issue vs. 2.73 Crore Shares OFS
The public offering structure outlined in the draft prospectus balances long-term corporate capacity enhancement with structured private equity monetization:
- Primary Growth Capital (₹800 Crore Fresh Issue): The ₹800.00 Crore primary proceeds will flow directly into Aragen’s corporate accounts. Contract research and biologics require substantial upfront capital investments in automated cleanrooms, high-resolution mass spectrometers, chromatography skids, and pilot bioreactors. Primary funds enable Aragen to aggressively expand capacity without taking on high-cost debt.
- Secondary Private Equity Liquidity (2.73 Crore Shares OFS): Selling shareholders will divest up to 2,73,29,192 equity shares. The principal selling shareholder is Goldman Sachs Capital Holdings III Pte. Ltd., which acquired a minority stake of approximately 33% from ChrysCapital in May 2021, alongside members of the founding promoter family. Proceeds from the OFS flow entirely to selling shareholders.
3. Objects of the Fresh Issue: Where Will the ₹800 Crore Go?
In Section IV of the draft prospectus, the management has established a focused capital deployment blueprint designed to curb interest charges while scaling high-margin biologics capacity:
| Proposed Expenditure Activity | Operating Entity & Facility Location | Strategic Corporate & Balance Sheet Impact |
|---|---|---|
| Prepayment / Repayment of Debt | Aragen Life Sciences Limited (Consolidated) | Extinguishes high-cost bank borrowings, directly lowering interest charges and expanding net profit margins. |
| Discovery Machinery & Equipment Capex | Hyderabad R&D Campuses (Mallapur & Nacharam) | Procuring automated robotic synthesisers, chromatography skids, and ultra-high-pressure mass spectrometers. |
| Biologics Manufacturing Suite Expansion | Aragen Biologics Private Limited (Bengaluru) | Augmenting mammalian cell culture and microbial fermentation bioreactors for large molecule clinical batches. |
| General Corporate Purposes (GCP) | Aragen Life Sciences Limited (Corporate) | Subject to SEBI statutory 25% cap; funds operating contingency reserves and software IP enhancements. |
4. Business Model & Global CRDMO Footprint: Small Molecules & Biologics
Aragen operates an integrated contract research and manufacturing service architecture serving over 450 pharmaceutical and biotechnology clients across the globe:
| Business Segment / Modality | Operational Capabilities & Campuses | Share of Revenue (FY2026) | Target Customer Profile & Modality |
|---|---|---|---|
| 1. Discovery Services (Small Molecules) | Integrated medicinal chemistry, computational drug design, in-vitro/in-vivo biology, DMPK, and safety toxicology at Hyderabad and Pune. | ~58.0% | Global top-20 pharmaceutical multinationals and innovative venture-backed biotech firms. |
| 2. Development & Manufacturing (CDMO) | Chemical process R&D, scale-up synthesis, custom clinical batches, and commercial active pharmaceutical ingredients (APIs) at Visakhapatnam and Hyderabad. | ~28.0% | Mid-tier pharma and innovators progressing investigational new drugs (IND) through Phase I-III human trials. |
| 3. Biologics & Large Molecules | Cell line development, protein analytics, process engineering, microbial fermentation, and mammalian cell culture at Bengaluru and Morgan Hill (USA). | ~14.0% | High-growth biologics innovators developing therapeutic antibodies, recombinant proteins, and gene therapy vectors. |
| Geographic Export Revenue Mix | United States (~62%), Europe (~24%), Rest of World (~14%) | 100.0% | Export-driven revenue model benefiting from global pharmaceutical supply chain diversification away from China. |
5. 3-Year Audited Financial Health: 27.26% EBITDA Margin & Healthy Profits
Aragen’s restated financial statements filed with SEBI showcase steady operational compounding, robust pricing power, and consistently high operating margins:
| Financial & Operational Metric | FY2024 (Audited) | FY2025 (Audited) | FY2026 (Audited DRHP) | Compounded Trajectory & Growth Analysis |
|---|---|---|---|---|
| Revenue from Operations | ₹1,655.20 Cr | ₹1,885.60 Cr | ₹2,178.39 Cr | 14.64% 2-year CAGR driven by biologics and integrated discovery |
| Operating EBITDA | ₹432.10 Cr | ₹504.80 Cr | ₹593.77 Cr | Consistent EBITDA growth reflecting operational automation |
| Operating EBITDA Margin (%) | 26.10% | 26.77% | 27.26% | +116 bps margin expansion via high-complexity chemistry projects |
| Profit After Tax (PAT / Net Profit) | ₹182.40 Cr | ₹215.30 Cr | ₹257.64 Cr | Net profit expanded by 41.2% across the 3-year audit period |
| Net Profit Margin (%) | 11.02% | 11.42% | 11.83% | Healthy double-digit bottom-line conversion |
| Consolidated Net Worth | ₹1,240.50 Cr | ₹1,490.20 Cr | ₹1,785.40 Cr | Robust balance sheet net worth ahead of primary IPO equity infusion |
| Return on Net Worth (RoNW %) | 14.70% | 14.45% | 14.43% | Solid capital efficiency across specialized scientific laboratory assets |
6. Institutional Peer Comparison: Aragen vs. Syngene, Divi's & Suven
To contextualize Aragen’s financial valuation, institutional investors benchmark the issuer against publicly traded Indian contract research and active pharmaceutical ingredient manufacturers:
| Company Name | FY26 Revenue (₹ Cr) | EBITDA Margin (%) | Return on Equity (RoE %) | Core Business Modality & Moat |
|---|---|---|---|---|
| Aragen Life Sciences Limited | ₹2,178.39 Cr | 27.26% | 14.43% | Integrated Discovery Chemistry, Biology & Biologics CRDMO |
| Syngene International Limited | ₹3,480.00 Cr | 29.50% | 14.20% | Dedicated R&D centers for global pharma & clinical biologics |
| Divi's Laboratories Limited | ₹8,650.00 Cr | 38.40% | 18.50% | High-volume commercial API manufacturing & custom synthesis |
| Suven Pharmaceuticals Limited | ₹1,340.00 Cr | 36.20% | 17.10% | Specialized contract chemistry & advanced intermediates |
| Sai Life Sciences Limited | ₹1,450.00 Cr | 24.80% | 12.40% | Small molecule discovery and commercial CDMO services |
7. Offering Parameters Awaiting Final Red Herring Prospectus (RHP)
Because this filing represents an initial draft stage (DRHP), key commercial pricing and application parameters remain subject to regulatory clearance and market timing:
Offering Parameters to be Finalized in Red Herring Prospectus
- Price Band & Cut-Off Price: To be fixed by the company and investment bankers through the 100% book-building process.
- Market Bid Lot Size: Application lot size and minimum retail outlay will be determined alongside the upper price cap.
- Public Bidding Window: Opening and closing dates await SEBI final observation clearance and RoC registration.
- Total OFS Rupee Valuation: Rupee value of the 2.73 Crore shares will be calculated upon price band finalization.
8. Strategic Competitive Moats vs. Inherent Biopharma CDMO Risks
Investors analyzing Aragen Life Sciences must evaluate its scientific capabilities against industry-specific headwinds:
Core Strategic Strengths
- Marquee Institutional Sponsor: Backed by Goldman Sachs (~33% stake), delivering global corporate governance and institutional credibility.
- Industry-Leading 27.26% EBITDA Margins: Demonstrates high pricing power in specialized discovery chemistry and biologics analytics.
- 450+ Global Customer Base: Deep multi-year partnerships with global top-20 pharma innovators and emerging biotech pioneers.
- Dual Modality Architecture: Fully equipped across small molecules and large molecule biologics to capture high-growth clinical pipelines.
Inherent Business & Sector Risks
- US Biotech Funding Cycles: Early-stage drug discovery spending remains sensitive to global interest rates and venture funding slowdowns.
- Regulatory Compliance & US FDA Audits: Manufacturing facilities in Visakhapatnam and Hyderabad are subject to strict periodic inspections.
- Foreign Exchange Exposure: Over 85% of revenue is denominated in foreign currencies (USD/EUR), exposing margins to FX volatility.
- Customer Project Attrition: Inherent drug discovery attrition means prospective clinical molecules may fail before reaching commercial scale.
9. Book Running Lead Managers & Statutory Registrars
The public offering is being managed by premier domestic and global investment banks:
- Book Running Lead Managers (BRLMs): Goldman Sachs (India) Securities Private Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and JM Financial Limited.
- Registrar to the Offer: KFin Technologies Limited, executing electronic bid collection, allotment reconciliation, and funds unblocking via ASBA/UPI.
- Statutory Auditors: Independent chartered accountancy firm certifying restated financial statements under Indian Accounting Standards (Ind AS).
- Legal Counsels: Shardul Amarchand Mangaldas & Co. and international legal advisors ensuring full SEBI ICDR and US Rule 144A compliance.
10. Statutory Regulatory Disclosures & Official Filing References
All financial disclosures, share counts, capital allocation numbers, and operational facility statistics cited in this report are sourced directly from regulatory filings:
- SEBI Public Issues Offer Document Archive: Aragen Life Sciences Limited Draft Red Herring Prospectus (DRHP Entry 26 August 2026) .
- National Stock Exchange of India (NSE): NSE Mainboard Public Issues Console .
- BSE Limited: BSE Mainboard Listed Companies Portal .
- Registrar Allotment Console: KFin Technologies IPO Allotment & Mandate Status Desk .
- Corporate Governance Portal: Aragen Life Sciences Official Investor Relations Portal .
Frequently Asked Questions (Institutional FAQ Desk)
Statutory Regulatory Disclosures & Editorial Standards
Source Attribution: Information published on Digital Arthalaya is curated from publicly filed Draft Red Herring Prospectuses (DRHP), Red Herring Prospectuses (RHP), Price Band Advertisements, and Official Stock Exchange (BSE/NSE) notifications.
Non-Advisory Mandate & Risk Warning: Digital Arthalaya is strictly an independent financial education portal and is not a SEBI-registered investment advisor or stock broker. IPO bidding and equity trading involve market risk, including potential loss of principal. Readers must conduct their own independent due diligence and read all offer documents carefully before making investment commitments.